Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells

ABSTRACT: Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells

PROVIDER: PRJNA512232 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells

Project description:Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation. However, the underlying cellular and molecular mechanisms remain unidentified. Here, we generated non-integrative induced pluripotent stem cells (iPSCs) from fibroblasts from a CADASIL patient harboring a heterozygous NOTCH3 mutation (c.3226C>T, p.R1076C). Vascular smooth muscle cells (VSMCs) differentiated from CADASIL-specific iPSCs showed transcriptional changes and disease-associated cellular dysfunction, including activation of the NF-kB signaling pathway, cytoskeleton disorganization, and excessive cell proliferation. In comparison, these abnormalities were not observed in vascular endothelial cells (VECs) derived from the patient’s iPSCs. Importantly, the abnormal upregulation of NF-kB target genes in CADASIL VSMCs was diminished by a NOTCH pathway inhibitor, providing a potential therapeutic strategy for CADASIL. Overall, using this iPSC-based disease model, our study identified clues for studying the disease mechanisms of CADASIL and developing treatment strategies for this disease.

2018-12-31 | GSE124500 | GEO

Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells.

Project description:Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare hereditary cerebrovascular disease caused by a NOTCH3 mutation. However, the underlying cellular and molecular mechanisms remain unidentified. Here, we generated non-integrative induced pluripotent stem cells (iPSCs) from fibroblasts of a CADASIL patient harboring a heterozygous NOTCH3 mutation (c.3226C>T, p.R1076C). Vascular smooth muscle cells (VSMCs) differentiated from CADASIL-specific iPSCs showed gene expression changes associated with disease phenotypes, including activation of the NOTCH and NF-κB signaling pathway, cytoskeleton disorganization, and excessive cell proliferation. In comparison, these abnormalities were not observed in vascular endothelial cells (VECs) derived from the patient's iPSCs. Importantly, the abnormal upregulation of NF-κB target genes in CADASIL VSMCs was diminished by a NOTCH pathway inhibitor, providing a potential therapeutic strategy for CADASIL. Overall, using this iPSC-based disease model, our study identified clues for studying the pathogenic mechanisms of CADASIL and developing treatment strategies for this disease.

| S-EPMC6418078 | biostudies-literature

Modeling Diabetic Endothelial Dysfunction with Patient-Specific Induced Pluripotent Stem Cells

Project description:Modeling Diabetic Endothelial Dysfunction with Patient-Specific Induced Pluripotent Stem Cells

| PRJNA990795 | ENA

Systems modeling of developmental vascular toxicity

Project description:Systems modeling of developmental vascular toxicity

| PRJNA547772 | ENA

UHRF1-mediated epigenetic regulation of smooth muscle cell modulates development of vascular pathologies

Project description:Adult vascular smooth muscle cells (VSMCs) dedifferentiate in response to extracellular cues such as vascular damage and inflammation. Dedifferentiated VSMCs are proliferative, migratory, less contractile, and can contribute to vascular repair as well as to cardiovascular pathologies such as intimal hyperplasia/restenosis in coronary artery and arterial aneurysm. We here demonstrate the role of ubiquitin-like containing PHD and RING finger domains 1 (UHRF1) as an epigenetic master regulator of VSMC plasticity. UHRF1 expression correlated with the development of vascular pathologies associated with modulation of noncoding RNAs, such as microRNAs. miR-145 — pivotal in regulating VSMC plasticity, which is reduced in vascular diseases — was found to control Uhrf1 mRNA translation. In turn, UHRF1 triggered VSMC proliferation, directly repressing promoters of cell-cycle inhibitor genes (including p21 and p27) and key prodifferentiation genes via the methylation of DNA and histones. Local vascular viral delivery of Uhrf1 shRNAs or Uhrf1 VSMC-specific deletion prevented intimal hyperplasia in mouse carotid artery and decreased vessel damage in a mouse model of aortic aneurysm. Our study demonstrates the fundamental role of Uhrf1 in regulating VSMC phenotype by promoting proliferation and dedifferentiation. UHRF1 targeting may hold therapeutic potential in vascular pathologies.

2018-12-05 | GSE99472 | GEO

Human immature neutrophils as a functional biomarker of systemic vascular pathologies

Project description:Human immature neutrophils as a functional biomarker of systemic vascular pathologies

| PRJNA622530 | ENA

Osteochondral Tissue Chip Derived from iPSCs: Modeling OA pathologies and Testing Drugs

Project description:Osteochondral Tissue Chip Derived from iPSCs: Modeling OA pathologies and Testing Drugs

| PRJNA589299 | ENA

Spatial transcriptomic profiling of Patient and Patient-corrected bioengineered vascular grafts.

Project description:Spatial transcriptomic profiling of two replicates of Patient and two replicates of Patient-corrected bioengineered vascular grafts harvested at week 8 post-implantation.

2024-05-08 | GSE216992 | GEO

Modeling Lung Adenocarcinoma Metastases Using Patient-Derived Organoids

Project description:Modeling Lung Adenocarcinoma Metastases Using Patient-Derived Organoids

| PRJNA1157185 | ENA

Spatial transcriptomic profiling of Patient and Patient-corrected bioengineered vascular grafts.

Project description:Spatial transcriptomic profiling of Patient and Patient-corrected bioengineered vascular grafts.

| PRJNA896541 | ENA